| NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) | ||||||
| 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: |
Hutchison China MediTech Limited; Legal Entity Identifier: 2138006X34YDQ6OBYE79 |
|||||
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | ||||||
| Non-UK issuer | X | |||||
| 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | ||||||
| An acquisition or disposal of voting rights | X | |||||
| An acquisition or disposal of financial instruments | ||||||
| An event changing the breakdown of voting rights | ||||||
| Other (please specify): | ||||||
| 3. Details of person subject to the notification obligation | ||||||
| Name | Prudential plc group of companies | |||||
| City and country of registered office (if applicable) | London, United Kingdom | |||||
| 4. Full name of shareholder(s) (if different from 3.) | ||||||
| Name | ||||||
| City and country of registered office (if applicable) | ||||||
| 5. Date on which the threshold was crossed or reached: | 25/07/2019 | |||||
| 6. Date on which issuer notified (DD/MM/YYYY): | 26/07/2019 | |||||
| 7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) | Total number of voting rights of issuer | |||
| Resulting situation on the date on which threshold was crossed or reached | 4.95% | 0.04% | 4.99% | 666,577,450 | ||
| Position of previous notification (if applicable) | 5.10% | 0.00% | 5.10% | |||
| 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached | |||||||||
| A: Voting rights attached to shares | |||||||||
| Class/type of sharesISIN code (if possible) |
Number of voting rights | % of voting rights | |||||||
|
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
||||||
| ORD USD0.10 KYG4672N1198 |
10,625,710 | 1.59% | |||||||
| SPON ADS US44842L1035 |
22,425,345 | 3.36% | |||||||
| SUBTOTAL 8. A | 33,051,055 | 4.95% | |||||||
| B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||
| Type of financial instrument | Expiration datex |
Exercise/ Conversion Periodxi |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights | |||
|
ORD USD0.10 KYG4672N1198 (Right of Recall) |
274,240 | 0.04% | |||||
| SUBTOTAL 8. B 1 | 274,240 | 0.04% | |||||
| B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||
| Type of financial instrument | Expiration datex |
Exercise/ Conversion Period xi |
Physical or cash settlementxii |
Number of voting rights | % of voting rights | ||
| SUBTOTAL 8.B.2 | |||||||
| 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) | ||||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer | ||||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) |
X | |||
| Name | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
|
Prudential plc (Parent Company) |
4.95% | 0.04% | 4.99% | |
|
M&G Prudential Limited (wholly owned subsidiary of Prudential plc) |
4.95% | 0.04% | 4.99% | |
|
M&G Group Limited (wholly owned subsidiary of Prudential plc) |
4.95% | 0.04% | 4.99% | |
|
M&G Limited (wholly owned subsidiary of M&G Group Limited) |
4.95% | 0.04% | 4.99% | |
|
M&G Investment Management Limited (wholly owned subsidiary of M&G Limited) |
4.95% | 0.04% | 4.99% | |
| 10. In case of proxy voting, please identify: | ||||
| Name of the proxy holder | N/A | |||
| The number and % of voting rights held | N/A | |||
| The date until which the voting rights will be held | N/A | |||
| 11. Additional information | ||||
| We no longer hold a notifiable interest. | ||||
| Place of completion | London, United Kingdom |
| Date of completion | 26 July 2019 |
伦敦：2019年7月30日(星期二): 和黄中国医药科技有限公司（Chi-Med）（AIM /纳斯达克股票代码: HCM）今天公布截至2019年6月30日的未经审核财务数据，并公布了关键临床项目的最新进展。重点包括：
和黄中国医药科技主席杜志强表示: “ 和黄中国医药科技目前在各方面的经营状况良好，未来的发展势头也很强劲。上半年的所有主要临床项目数据都令人鼓舞，尤其是索凡替尼以非胰腺神经内分泌瘤为适应症的III 期临床研究结果，以及沃利替尼治疗MET外显子14缺失的非小细胞肺癌初步研究数据完成，并预期于2019年底完成入组。我们相信这些成果有望推进和黄中国医药科技在今年年底及明年初分别为索凡替尼和沃利替尼提出新药上市申请。”
“由于沃利替尼与泰瑞莎®联合疗法在治疗非小细胞肺癌的初步临床研究数据令人满意，合作伙伴阿斯利康于今年初启动名为SAVANNAH的全球注册临床研究。此外，近期公布的沃利替尼与Imfinzi®联合疗法在治疗肾癌方面的初步数据亦令人鼓舞。”
“我们首个获批的肿瘤药物爱优特®的销售表现不俗。就推出后首六个月的销售表现而言，爱优特®的销售额远超其他五个由跨国药企在中国推出的小分子VEGFR抑制剂3。我们认为爱优特®凭借其出众的疗效及安全性，加之其有望被纳入国家医保药品目录，假以时日将成为市场中强大的竞争者。”
“我们的商业平台如常运作。相比去年同期，按固定汇率4计算，净收入增长9％。这笔收入为我们的临床开发项目及研发平台提供了重要的资金。今年，我们提交了新型异柠檬酸脱氢酶(IDH) 1/2 抑制剂6 HMPL-306的新药临床试验(IND) 申请5，为我们的肿瘤药物管线再添第九个成员。”
“公司正在迅速发展，我们于美国新泽西的全球临床及注册团队不断壮大，以负责索凡替尼和呋喹替尼的全球注册研究以及B细胞恶性肿瘤药物的早期开发。我们在中国的肿瘤业务商业团队亦在迅速扩张，负责管理医疗事务，并为明年底可能推出索凡替尼做好准备。”
“展望未来两年，我们期望加快转型成为一家全面综合、面向全球的生物医药公司，发现、开发及商业化多种创新药物，致力于满足不同的医疗需求，令广大患者受惠。”
[1]爱优特® 的中国市场的销售额由礼来提供。
[2]间充质上皮转化因子 (Mesenchymal Epithelial Transition Factor, MET)
[3]血管内皮生长因子受体 (Vascular Endothelial Growth Factor Receptor, VEGFR)
[4] 固定汇率(“CER”)。本公告中的若干财务资料乃按固定汇率或CER呈列。这些财务指标并非按照美国公认会计原则（GAAP）呈报，因为它们从我们报告的结果中消除了汇率变动的影响。请参阅下文「使用非GAAP财务指标和调节」，以获取有关这些财务指标的解释的相关资料，以及这些财务指标与最具可比性的GAAP指标的对账;
[5]新药临床试验 (Investigational New Drug, IND)
[6]异柠檬酸脱氢酶 (Isocitrate dehydrogenase, IDH)1和2
| 公告发布： 7am BST (2pm HKT/2am EDT) |
| >> 查看公告 << |
| 简报会网络直播及电话会议： 9am BST (4pm HKT/4am EDT) |
| 观看网络直播回放 |
| 美国电话会议： 9am EDT (2pm BST/9pm HKT) |
| — |
To participate by phone, please use one of the following numbers. The conference ID for the calls is “Chi-Med“.
| China Toll Free | 4001 200558 |
| Hong Kong Toll Free | 800 900 476 |
| New York | +1 212 999 6659 |
| Italy Toll Free | 800 986 477 |
| Singapore Toll Free | 800 120 4789 |
| Standard International Access | +44 (0) 20 3003 2666 |
| Switzerland Toll Free | 0800 800 038 |
| UK Toll Free | 0808 109 0700 |
| USA Toll Free | 1 866 966 5335 |
| NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) | ||||||
| 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: | Hutchison China MediTech Limited; Legal Entity Identifier: 2138006X34YDQ6OBYE79 |
|||||
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | ||||||
| Non-UK issuer | X | |||||
| 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | ||||||
| An acquisition or disposal of voting rights | X | |||||
| An acquisition or disposal of financial instruments | ||||||
| An event changing the breakdown of voting rights | ||||||
| Other (please specify): | ||||||
| 3. Details of person subject to the notification obligation | ||||||
| Name | Hutchison Healthcare Holdings Limited | |||||
| City and country of registered office (if applicable) | British Virgin Islands | |||||
| 4. Full name of shareholder(s) (if different from 3.) | ||||||
| Name | ||||||
| City and country of registered office (if applicable) | ||||||
| 5. Date on which the threshold was crossed or reached: | 02/07/2019 | |||||
| 6. Date on which issuer notified (DD/MM/YYYY): | 02/07/2019 | |||||
| 7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) | Total number of voting rights of issuer | |||
| Resulting situation on the date on which threshold was crossed or reached | 51.15% | 51.15% | 666,577,450 | |||
| Position of previous notification (if applicable) | 60.36% | – | 60.36% | |||
| 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached | |||||||||
| A: Voting rights attached to shares | |||||||||
| Class/type of sharesISIN code (if possible) |
Number of voting rights | % of voting rights | |||||||
|
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
||||||
| Ordinary Shares (KYG4672N1198) |
340,978,770 | – | 51.15% | – | |||||
| American Depositary Shares (US44842L1035) |
– | – | – | – | |||||
| SUBTOTAL 8. A | 340,978,770 | 51.15% | |||||||
| B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
| Type of financial instrument | Expiration datex |
Exercise/ Conversion Period |
Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
| SUBTOTAL 8. B 1 | |||||||||
| B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||||
| Type of financial instrument | Expiration datex |
Exercise/ Conversion Period |
Physical or cash settlement | Number of voting rights | % of voting rights | ||||||
| SUBTOTAL 8.B.2 | |||||||||||
| 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) | ||||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer | ||||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) |
X | |||
| Name | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
| CK Hutchison Holdings Limited – indirect, but ultimate, owner of the shareholder | 51.15% | 51.15% | ||
| Hutchison Whampoa (China) Limited – direct owner of the shareholder and a subsidiary of CK Hutchison Holdings Limited | 51.15% | 51.15% | ||
| 10. In case of proxy voting, please identify: | ||||
| Name of the proxy holder | ||||
| The number and % of voting rights held | ||||
| The date until which the voting rights will be held | ||||
| 11. Additional information | ||||
|
|
||||
| Place of completion | Hong Kong |
| Date of completion | 3 July 2019 |
| NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) | ||||||
| 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: |
Hutchison China MediTech Limited; Legal Entity Identifier: 2138006X34YDQ6OBYE79 |
|||||
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | ||||||
| Non-UK issuer | X | |||||
| 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | ||||||
| An acquisition or disposal of voting rights | X | |||||
| An acquisition or disposal of financial instruments | ||||||
| An event changing the breakdown of voting rights | ||||||
| Other (please specify): | ||||||
| 3. Details of person subject to the notification obligation | ||||||
| Name | Prudential plc group of companies | |||||
| City and country of registered office (if applicable) | London, United Kingdom | |||||
| 4. Full name of shareholder(s) (if different from 3.) | ||||||
| Name | ||||||
| City and country of registered office (if applicable) | ||||||
| 5. Date on which the threshold was crossed or reached: | 28/06/2019 | |||||
| 6. Date on which issuer notified (DD/MM/YYYY): | 01/07/2019 | |||||
| 7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) | Total number of voting rights of issuer | |||
| Resulting situation on the date on which threshold was crossed or reached | 5.10% | 0.00% | 5.10% | 666,577,450 | ||
| Position of previous notification (if applicable) | N/A | N/A | N/A | |||
| 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached | |||||||||
| A: Voting rights attached to shares | |||||||||
| Class/type of sharesISIN code (if possible) |
Number of voting rights | % of voting rights | |||||||
|
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
||||||
| ORD USD0.10 KYG4672N1198 |
10,899,950 | 1.63% | |||||||
| SPON ADS US44842L1035 |
23,141,235 | 3.47% | |||||||
| SUBTOTAL 8. A | 34,041,185 | 5.10% | |||||||
| 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) | ||||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer | ||||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) |
X | |||
| Name | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
|
Prudential plc (Parent Company) |
5.10% | 0.00% | 5.10% | |
|
M&G Prudential Limited (wholly owned subsidiary of Prudential plc) |
5.10% | 0.00% | 5.10% | |
|
M&G Group Limited (wholly owned subsidiary of Prudential plc) |
5.10% | 0.00% | 5.10% | |
|
M&G Limited (wholly owned subsidiary of M&G Group Limited) |
5.10% | 0.00% | 5.10% | |
|
M&G Investment Management Limited (wholly owned subsidiary of M&G Limited) |
5.10% | 0.00% | 5.10% | |
| 10. In case of proxy voting, please identify: | ||||
| Name of the proxy holder | N/A | |||
| The number and % of voting rights held | N/A | |||
| The date until which the voting rights will be held | N/A | |||
| 11. Additional information | ||||
|
|
||||
| Place of completion | London, United Kingdom |
| Date of completion | 01 July 2019 |
London: Wednesday, July 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm Hong Kong Time (HKT); 2:00 am Eastern Daylight Time (EDT)).
An analyst presentation will be held at 9:00 am BST (4:00 pm HKT) on the same day at Citigate Dewe Rogerson, 8th Floor, Holborn Gate, 26 Southampton Buildings, London WC2A 1AN, UK, which will be webcast via the company website at www.chi-med.com/investors/event-information/. The presentation will be available to download before the analyst presentation begins.
For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am EDT (2:00 pm BST).
Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement. A replay will also be available on the website shortly after each event.
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 440 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.
Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.
Mark Lee, Senior Vice President, Corporate Finance & Development
+852 2121 8200
Annie Cheng, Vice President, Corporate Finance & Development
+1 (973) 567 3786
David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout
+1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
UK & Europe – Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas – Brad Miles, Solebury Trout
+1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Hong Kong & Asia ex-China – Joseph Chi Lo, Brunswick
+852 9850 5033 (Mobile)
jlo@brunswickgroup.com
Hong Kong & Asia ex-China – Zhou Yi, Brunswick
+852 9783 6894 (Mobile)
yzhou@brunswickgroup.com
Mainland China – Sam Shen, Edelman
+86 1367 179 1029 (Mobile)
sam.shen@edelman.com
Richard Gray / Atholl Tweedie, Panmure Gordon (UK) Limited
+44 (20) 7886 2500